

NHL	Vendor Name	Gender	Age	Histology subtypes	Grade	positive Marker's	Site
NHL17001	530-A992	M	75	Mantle cell lymphoma (MCL)	typical not aggressive	CD19, CD20, CD5, CYCLIN-D+	Left Groin
NHL17002	530-A993	F	55	Follicular lymphoma (FL)	1	CD20, CD10, BCL2	Left level III
NHL17003	850-8104	M	63	Follicular lymphoma (FL)	1-2 of 3	BCL-1, BCL-2, BCL-6, CD3, CD5, CD10, CD20, CD21, CD43, PAX5	Right arm (soft tissue mass)
NHL17004	310-E799	M	62	Follicular lymphoma (FL)	not described	CD3, CD5, CD10, CD15, CD20, CD30, CD45, Pax-5, Ki-67	Right level II mass, Right posterior mass (excision)
NHL17005	850-8327	F	33	Diffuse large B-cell lymphoma (DLBCL)	High grade large B cell lymphoma	BCL1, BCL2, BCL6, CD3, CD20, C-MYC, CD30, MUM-1	Mediastinal Mass

Fig. 1




FIG. 2




FIG. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8

TIL type	LY56	
	IL-5	IL-6
Melanoma TIL	IL-5	IL-6
	IL-5	IL-6
	IL-5	IL-6
	IL-5	IL-6
	IL-5	IL-6
	IL-5	IL-6
	IL-5	IL-6
Lymphoma TIL	IL-5	IL-6
	IL-5	IL-6
	IL-5	IL-6
	IL-5	IL-6
	IL-5	IL-6




FIG. 10




Fig. 11




FIG. 12




FIG. 13




Fig. 14




FIG. 15

FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG. 17A CD27+




FIG. 17B CD28+




FIG. 18A




FIG. 18B




FIG. 19A





FIG. 19B






FIG. 20A




FIG. 20B




FIG. 20C




FIG. 20D





FIG. 21



၇၇

FIG. 23

Process 2A: about 22 days from Steps A - E

1. STEP A

Obtain Patient Tumor Sample

2. STEP B

Fragmentation and First Expansion

3 days to 14 days

3. STEP C

First Expansion to Second Expansion Transition

No Storage and Closed System

4. STEP D

Second Expansion

IL-2, OX40, and antigen-presenting feeder cells

Closed System

5. STEP E

Harvest TILs from Step D

Closed System

6. STEP F

Final Formulation and/or Transfer to Infusion Bag

(optionally cryopreserve)

FIG. 24A

Method 1




FIG. 24B

Method 2




FIG. 24C




FIG. 25A





FIG. 25B






FIG. 26










FIG. 27





29









FIG. 31A







FIG. 31B



236



226







FIG. 34B





FIG. 34A






FIG. 35B




FIG. 35A

FIG. 36A




FIG. 36B




FIG. 37A















FIG. 37B
















FIG. 42A

FIG. 42C

FIG. 43B




FIG. 44B




FIG. 43A








FIG. 44A





Timeline - CLL PBL expansion process



- Method 1
- Thaw PBMC
 - Isolate T cells (bead method - negative selection)
 - Culture T cells only in the presence of α CD3/ α CD28 beads (1:1 ratio) and IL-2
- Method 2
- Thaw PBMC
 - Isolate CD19+ B cells (bead method - positive selection)
 - Isolate T cells (bead method - negative selection)
 - Coculture T cells and B cells in the presence of α CD3/ α CD28 beads (1:1 ratio) and IL-2

FIG. 47

Timeline - AML MIL expansion process




FIG. 48